

Jonathan E Koltz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8474041/publications.pdf>

Version: 2024-02-01

106
papers

2,791
citations

279798

23
h-index

182427

51
g-index

107
all docs

107
docs citations

107
times ranked

4179
citing authors

#	ARTICLE	IF	CITATIONS
1	CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.	1.6	682
2	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 755-764.	8.2	515
3	Chronic Lymphocytic Leukemia Cells Recognize Conserved Epitopes Associated with Apoptosis and Oxidation. <i>Molecular Medicine</i> , 2008, 14, 665-674.	4.4	174
4	Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells. <i>Molecular Medicine</i> , 2011, 17, 1374-1382.	4.4	140
5	P-glycoprotein inhibition using valsopodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. <i>Blood</i> , 2010, 116, 1413-1421.	1.4	113
6	Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 5201-5210.	1.4	110
7	Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. <i>Blood Advances</i> , 2018, 2, 1645-1650.	5.2	85
8	Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. <i>Leukemia</i> , 2018, 32, 1338-1348.	7.2	80
9	Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ <i>KMT2A</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26340-26346.	7.1	59
10	Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically. <i>Leukemia</i> , 2019, 33, 1620-1634.	7.2	55
11	IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. <i>Blood</i> , 2012, 120, 4802-4811.	1.4	52
12	TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. <i>Journal of Immunology</i> , 2015, 195, 901-923.	0.8	47
13	Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. <i>Blood Advances</i> , 2020, 4, 696-705.	5.2	44
14	SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 901-901.	1.4	42
15	Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2021, 11, 626-637.	9.4	41
16	Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. <i>Blood</i> , 2009, 114, 3615-3624.	1.4	37
17	NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. <i>Leukemia</i> , 2018, 32, 2536-2545.	7.2	33
18	Neutropenic Enterocolitis in Adult Patients with Acute Leukemia: A Single Center Experience. <i>Blood</i> , 2012, 120, 4324-4324.	1.4	31

#	ARTICLE	IF	CITATIONS
19	A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4129-4129.	1.4	30
20	Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical Th1-dependent, Bcl-6-deficient process. <i>JCI Insight</i> , 2016, 1, .	5.0	29
21	Clinical and functional significance of circular RNAs in cytogenetically normal AML. <i>Blood Advances</i> , 2020, 4, 239-251.	5.2	29
22	Carfilzomib-related acute kidney injury may be prevented by N-acetyl-L-cysteine. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 313-316.	0.9	26
23	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. <i>Leukemia</i> , 2021, 35, 3163-3175.	7.2	25
24	Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. <i>Cancer</i> , 2016, 122, 2379-2388.	4.1	23
25	Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 721-729.	3.5	21
26	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. <i>Leukemia</i> , 2021, 35, 1037-1052.	7.2	19
27	A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 90-100.	2.9	18
28	Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion. <i>Journal of Immunology</i> , 2018, 201, 1570-1585.	0.8	16
29	Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes. <i>Immunologic Research</i> , 2015, 63, 216-227.	2.9	15
30	Binding of CLL Subset 4 B Cell Receptor Immunoglobulins to Viable Human Memory B Lymphocytes Requires a Distinctive IGKV Somatic Mutation. <i>Molecular Medicine</i> , 2017, 23, 1-12.	4.4	14
31	Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7035-7035.	1.6	14
32	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021, 11, 640731.	2.8	12
33	Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status. <i>Clinical Immunology</i> , 2016, 172, 44-51.	3.2	11
34	A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 627020.	4.8	11
35	A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7001-7001.	1.6	10
36	Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins. <i>Journal of Immunology</i> , 2019, 202, 2924-2944.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Longitudinal Analyses of CXCR4dimCD5brCD19+ Fractions of Chronic Lymphocytic Leukemia Clones Reveal Features Consistent with a Source of Clonal Heterogeneity. <i>Blood</i> , 2011, 118, 804-804.	1.4	9
38	Mantle cell lymphoma with in situ or mantle zone growth pattern: a study of five cases and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 1042-50.	0.5	9
39	Clinical and molecular characterization of patients with acute myeloid leukemia and sole trisomies of chromosomes 4, 8, 11, 13 or 21. <i>Leukemia</i> , 2020, 34, 358-368.	7.2	8
40	Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1451-1459.	4.1	7
41	Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. <i>Journal of Hematology and Oncology</i> , 2021, 14, 107.	17.0	6
42	A precision medicine classification for treatment of acute myeloid leukemia in older patients. <i>Journal of Hematology and Oncology</i> , 2021, 14, 96.	17.0	5
43	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016, 128, 1166-1166.	1.4	5
44	Primary extranodal marginal zone lymphoma of the endometrium: report of four cases and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3036-44.	0.5	5
45	Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia. <i>Nucleic Acids Research</i> , 2020, 48, e40-e40.	14.5	4
46	Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 1034-1044.	3.5	4
47	CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By Bruton's Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrutinib. <i>Blood</i> , 2019, 134, 477-477.	1.4	4
48	Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance). <i>Blood</i> , 2020, 136, 5-7.	1.4	4
49	Phase II Study of Bortezomib Added to Standard Daunorubicin and Cytarabine Induction and Dose Escalation of Bortezomib with Intermediate-Dose Cytarabine Consolidation Therapy for Patients with Previously Untreated Acute Myeloid Leukemia Age 60â€“75 Years: Cancer and Leukemia Group B (CALGB) Study 10502. <i>Blood</i> , 2010, 116, 331-331.	1.4	4
50	Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells. <i>Blood</i> , 2011, 118, 975-975.	1.4	4
51	Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance). <i>Blood</i> , 2012, 120, 44-44.	1.4	4
52	Ultra-Deep Sequencing of De Novo IGHV Mutations in Activated CLL Cells: Evidence for Activation-Induced Deaminase Function.. <i>Blood</i> , 2012, 120, 2545-2545.	1.4	4
53	CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors. <i>Blood</i> , 2012, 120, 3626-3626.	1.4	3
54	Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction. <i>Blood</i> , 2016, 128, 3955-3955.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).. Journal of Clinical Oncology, 2017, 35, 7036-7036.	1.6	3
56	Efficacy and Safety of Hydroxychloroquine Sulphate In Chronic Lymphocytic Leukemia: Clinical Trial Experience In Untreated Patients. Blood, 2010, 116, 1392-1392.	1.4	3
57	Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutations. Leukemia, 2021, 35, 1188-1192.	7.2	2
58	A 17-Gene Leukemia Stem Cell (LSC) Score in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Reveals a Distinct Mutational Landscape and Refines Current European Leukemianet (ELN) Genetic Risk Stratification. Blood, 2018, 132, 289-289.	1.4	2
59	Sole Trisomy 8 In Patients (pts) with De Novo Acute Myeloid Leukemia (AML) Is Associated with Age-Independent Poor Outcome That Is Modified by Molecular Markers and with Unique Gene- and MicroRNA (miR)-Signatures: a Cancer and Leukemia Group B (CALGB) Study. Blood, 2010, 116, 577-577.	1.4	2
60	Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts). Blood, 2011, 118, 414-414.	1.4	2
61	Multivariate analysis of factors affecting overall survival, event free survival, and 60-day mortality among AML patients treated with CPX-351 or intensive chemotherapy.. Journal of Clinical Oncology, 2013, 31, 7100-7100.	1.6	2
62	Activated CLL cells regulate IL-17Fâ€“producing Th17 cells in miR155-dependent and outcome-specific manners. JCI Insight, 2022, 7, .	5.0	2
63	The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment. Blood, 2019, 134, 2681-2681.	1.4	1
64	Elevated IL-17 Producing Cells (Th17 and Non-Th17) In Different CLL Microenvironments: Correlation with Overall Survival, Prognostic Relevance and Phenotypic Heterogeneity. Blood, 2010, 116, 2442-2442.	1.4	1
65	The Clinical Role of Micronas (miRs) in Cytogenetically Normal (CN) Acute Myeloid Leukemia (AML): miR-155 Upregulation Independently Identifies High-Risk Patients (Pts). Blood, 2012, 120, 1387-1387.	1.4	1
66	CLL Sera Drive Maturation of Normal Monocytes to M2-like Macrophages By Direct and Indirect Mechanisms. Blood, 2014, 124, 1970-1970.	1.4	1
67	A comparison of CR versus CRi response following CPX-351 treatment of newly diagnosed AML in elderly patients (pts).. Journal of Clinical Oncology, 2012, 30, 6601-6601.	1.6	1
68	Somatic Hypermutation In Stereotyped Subset 4 BCRs/mAbs of CLL Patients, Expressing IGHV4-34 gene, Edit Anti-DNA Reactivity. Blood, 2010, 116, 2444-2444.	1.4	1
69	TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity,. Blood, 2011, 118, 3690-3690.	1.4	1
70	Lenalidomide Promotes The Expansion Of CD8 T Cells With An Effector Memory Phenotype In a Murine Xenograft Model Of Chronic Lymphocytic Leukemia. Blood, 2013, 122, 119-119.	1.4	1
71	Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance). Blood, 2019, 134, 1247-1247.	1.4	1
72	Elevated Binding of Chronic Lymphocytic Leukemia Antibody to a Subset of Apoptotic Cells with Exposed Non-Muscle Myosin Heavy Chain IIA Correlates with Poor Patient Outcome.. Blood, 2009, 114, 799-799.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Detection of Activation-Induced Cytidine Deaminase RNA In CLL Cells Correlates with Shorter Patient Survival and High Numbers of CD38+ Cells. <i>Blood</i> , 2010, 116, 2415-2415.	1.4	0
74	Chronic Lymphocytic Leukemia B Cells Variably Express Functional Activation-Induced Cytosine Deaminase Protein. <i>Blood</i> , 2010, 116, 378-378.	1.4	0
75	Mutations In the Tet Oncogene Family Member 2 (TET2) Gene Refine the New European LeukemiaNet Risk Classification of Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) In Adults: A Cancer and Leukemia Group B (CALGB) Study. <i>Blood</i> , 2010, 116, 98-98.	1.4	0
76	Some CLL Cells Bind Myosin-Exposed Apoptotic Cells. Exposure of Cytoplasmic Myosin Results From Transfer of Caspase-3 Dependent Cleavage Products to the Outer Cell Membrane. <i>Blood</i> , 2010, 116, 3900-3900.	1.4	0
77	Poor Outcome of RUNX1-Mutated (RUNX1-mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,. <i>Blood</i> , 2011, 118, 3454-3454.	1.4	0
78	Co-Culture of CLL Cells with MEACs (Myosin Heavy Chain IIA Exposed Apoptotic Cells) Promotes Viability of Leukemic Clones. <i>Blood</i> , 2011, 118, 624-624.	1.4	0
79	Cytogenetic, Molecular and Clinical Features Associated with Rare CBFβ-MYH11 Fusion Transcripts in Patients (Pts) with Acute Myeloid Leukemia (AML) and inv(16)/t(16;16). <i>Blood</i> , 2011, 118, 2514-2514.	1.4	0
80	Gene Set Enrichment Analysis of Ki-67high CLL Clones Suggests Complex Interactions of B-Cell Receptor Signaling and Normal Cell Interactions in the Disease. <i>Blood</i> , 2011, 118, 2833-2833.	1.4	0
81	Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients. <i>Blood</i> , 2011, 118, 2619-2619.	1.4	0
82	Successful Therapy of Cold Agglutinin Disease Utilizing Rituximab. <i>Blood</i> , 2011, 118, 5271-5271.	1.4	0
83	Retrospective Survival of Patients with Primary Central Nervous System Lymphoma (PCNSL) Treated with Upfront Chemoimmunotherapy (R+MVP) and without Radiation: North Shore - LIJ University Hospital From 2006 to 2011. <i>Blood</i> , 2011, 118, 4958-4958.	1.4	0
84	ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet "Favorable" Genetic Category. <i>Blood</i> , 2011, 118, 417-417.	1.4	0
85	CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report. <i>Blood</i> , 2011, 118, 254-254.	1.4	0
86	Effect of age on the pharmacokinetics of busulfan (Bu): An alliance study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2533-2533.	1.6	0
87	A phase II study of bortezomib added to standard daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine (Int-DAC) for consolidation in patients with previously untreated acute myeloid leukemia (AML) age 60-75 years: CALGB study 10502.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6526-6526.	1.6	0
88	Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigator's choice—A subset analysis by prognostic group.. <i>Journal of Clinical Oncology</i> , 2012, 30, 6525-6525.	1.6	0
89	Human CLL Intraclonal Fractions Differ in Their Abilities to Respond to, Elicit, and Suppress Pro-Engraftment and Growth Signals From Autologous T Cells in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 316-316.	1.4	0
90	CLL Cells Can Diversify, Switch, and Differentiate in Response to Autologous T Cell Stimuli Present in a Murine Adoptive Transfer Model. <i>Blood</i> , 2012, 120, 315-315.	1.4	0

#	ARTICLE	IF	CITATIONS
91	CLL Cell Viability Promoted by Myosin Heavy Chain IIA Exposed Apoptotic Cells is BTK-dependent. <i>Blood</i> , 2012, 120, 1767-1767.	1.4	0
92	Apparent Involvement Of The Interferon, RNA Processing, and Wnt Signaling Pathways In Monoclonal B Lymphocytosis. <i>Blood</i> , 2013, 122, 4157-4157.	1.4	0
93	Evaluation of IGHV Ultra-Deep Sequences for Activation-Induced Deaminase Characteristics in CLL Cells after T Cell Stimulation. <i>Blood</i> , 2013, 122, 2583-2583.	1.4	0
94	Concomitant, T-Independent TLR9-Mediated and BCR-Mediated Activation Provides Signals For Optimal Telomerase Induction In Chronic Lymphocytic Leukemia Cells Regardless Of IGHV Mutation Status. <i>Blood</i> , 2013, 122, 4142-4142.	1.4	0
95	Chronic Lymphocytic Leukemia Patients Exhibit Expanded Functional Granulocyte-like Myeloid Derived Suppressor Cells. <i>Blood</i> , 2014, 124, 3279-3279.	1.4	0
96	TLR-9 and IL-15-Driven Clonal Expansion of B-CLL Cells. <i>Blood</i> , 2014, 124, 1937-1937.	1.4	0
97	Ibrutinib for Transformed Lymphoma; A Report of 4 Patients. <i>Blood</i> , 2015, 126, 5115-5115.	1.4	0
98	Chronic Lymphocytic Leukemia Patients and E μ -TCL1 Mice Share a Phenotype of Functional Granulocyte-like and Dysfunctional Monocyte-like Myeloid Derived Suppressor Cells. <i>Blood</i> , 2015, 126, 614-614.	1.4	0
99	The RNA Binding Protein Musashi 2 Is up-Regulated in the Proliferative B-Cell Fraction of Chronic Lymphocytic Leukemia Clones. <i>Blood</i> , 2015, 126, 4149-4149.	1.4	0
100	Prognostic and Biologic Significance of Long Non-Coding RNA (lncRNA) Profiling in Cytogenetically Abnormal Acute Myeloid Leukemia (CA-AML). <i>Blood</i> , 2018, 132, 2767-2767.	1.4	0
101	Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic MicRNAs (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML). <i>Blood</i> , 2019, 134, 2694-2694.	1.4	0
102	Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL. <i>Blood</i> , 2021, 138, 2625-2625.	1.4	0
103	Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL. <i>Blood</i> , 2021, 138, 2622-2622.	1.4	0
104	Meta-Analysis of Genome-Wide Association Studies of Acute Myeloid Leukemia (AML) Patients Identifies Variants Associated with Risk of 11q23/KMT2A-Translocated and Core-Binding Factor (CBF) AML and Suggests a Role for Transcription Elongation in Leukemogenesis. <i>Blood</i> , 2020, 136, 29-30.	1.4	0
105	Differential Impact of Prognostically Significant Gene Mutations in Acute Myeloid Leukemia (AML) Patients (Pts) Older Than 70 Years (y) Treated with Cytarabine-Based Induction Therapy. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
106	Enrollment disparities in non-Hodgkin lymphoma clinical trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18594-e18594.	1.6	0